

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



New Ray Medicine  
新銳醫藥

## **New Ray Medicine International Holding Limited**

**新銳醫藥國際控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 6108)**

### **CHANGE OF AUDITORS**

The Board announces that Deloitte has resigned as the auditor of the Group with effect from 30 January 2018.

The Board also announces that, with the recommendation of the audit committee of the Board, Moore Stephens has been appointed as the new auditor of the Group with effect from 30 January 2018 to fill the casual vacancy following the resignation of Deloitte and to hold office until conclusion of the next annual general meeting of the Company.

This announcement is made by New Ray Medicine International Holding Limited (the “**Company**”, together with its subsidiaries, referred to as the “**Group**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors (“**Directors**”) of the Company (“**Board**”) announces that Deloitte Touche Tohmatsu (“**Deloitte**”) has resigned as the auditor of the Group with effect from 30 January 2018. The Board also announces that, with the recommendation of the audit committee of the Board, Moore Stephens CPA Limited (“**Moore Stephens**”) has been appointed as the new auditor of the Group with effect from 30 January 2018 to fill the casual vacancy following the resignation of Deloitte and to hold office until conclusion of the next annual general meeting of the Company.

Deloitte stated in their letter of resignation that, as part of their normal procedures which include an annual consideration of whether they would continue to act for their audit clients, having taken into account many factors including the professional risk associated with the audit, the level of audit fees and their available internal resources in light of their current work flows, they decided to tender their resignation as the auditor of the Group.

Deloitte, in their letter of resignation, also confirmed that there are no matters in connection with their resignation that need to be brought to the attention of holders of securities or creditors of the Company.

The Board has confirmed that there is no disagreement or unresolved matter between the Company and Deloitte, and that they are not aware of any matters in relation to the resignation of Deloitte as auditor of the Group that need to be brought to the attention of holders of securities of the Company.

The Board would like to take this opportunity to express its sincere gratitude to Deloitte for their professional services and support rendered to the Group in the past years.

On behalf of the Board  
**New Ray Medicine International Holding Limited**  
**Zhou Ling**  
*Chairman & Executive Director*

Hong Kong, 30 January 2018

*As of the date of this announcement, the executive Directors are Mr. Zhou Ling and Ms. Yang Fang; and the independent non-executive Directors are Mr. Ho Hau Cheung, SBS, MH, Mr. Leung Chi Kin and Ms. Li Sin Ming, Ivy.*